A pharmaceutical composition for treating IL-6-related diseases having as an active ingredient an IL-6 inhibitor, wherein the pharmaceutical composition is administered as usual after a short-interval dosing period where the same dose as the usual dose is administered at a shorter interval than the usual dosing interval.